share_log

B of A Securities Reinstates Underperform on Regeneron Pharmaceuticals, Announces $565 Price Target

B of A Securities Reinstates Underperform on Regeneron Pharmaceuticals, Announces $565 Price Target

美国银行证券重新评级再生元制药公司为跑输大盘,并宣布目标价格为565美元
Benzinga ·  2024/12/10 20:32  · 评级/大行评级

B of A Securities analyst Tim Anderson reinstates Regeneron Pharmaceuticals (NASDAQ:REGN) with a Underperform and announces $565 price target.

美银证券分析师TIM安德森重新将再生元制药公司(纳斯达克:REGN)定为表现不佳,并宣布目标价为565美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发